Last Price | 8.40 | Max Price | 9.57 |
Min Price | 7.92 | 1 Year return | -7.08 |
Sector | Health Care | Subsector | Pharmaceuticals |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 855 | 615,670 | 0.14 % |
2020 | 807 | 638,104 | 0.13 % |
2021 | 827 | 727,997 | 0.11 % |
2022 | 863 | 787,317 | 0.11 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
Over the period from December 2015 till December 2016 the stock lost around 22 percent. Over the past 5 years Almirall' stock rose at around 201 percent in value. Almirall's revenues between 2011 and 2015 were relatively stable and moved between 682,88 million euros and 684,99 million euros. Almirall's net results between 2011 and 2015 were quite unstable and moved between 84,17 million euros and 131,83 million euros.
Between 2006 and 2016 the global pharmaceutical companies gained around 75 percent. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.
The Spanish company paid out dividends in the past 5 years. On average the Almirall stock yielded a delivered a dividend yield of around 0,71 percent over the past 5 years.
At the end of 2015 the pharmaceutical company's balance sheet equaled 2,53 billion euros. 1,07 billion euros (42,24 percent of the total balance sheet) was financed by debt. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 35. So the stock' value was 35 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Spanish stock can be seen as a value stock.
At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 3,22 billion euros. At the end of 2015 around 172,95 million stocks were listed.
All Almirall's annual reports can be found here. More information about Almirall can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
685
|
764
|
639
|
757
|
855
|
807
|
Costs |
553
|
689
|
943
|
679
|
749
|
733
|
Profit |
132
|
75
|
-304
|
78
|
106
|
74
|
Margin of profit |
19.25
|
9.87
|
-47.54
|
10.26
|
12.38
|
9.20
|
ROI |
9.01
|
4.96
|
-26.81
|
6.52
|
8.27
|
5.70
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
1,463
|
1,520
|
1,134
|
1,192
|
1,280
|
1,303
|
Debt |
1,070
|
1,298
|
1,043
|
1,198
|
1,160
|
988
|
Total assets |
2,532
|
2,819
|
2,176
|
2,390
|
2,440
|
2,291
|
Solvency |
57.76
|
53.94
|
52.09
|
49.87
|
52.47
|
56.87
|
Cash |
868
|
467
|
280
|
86
|
117
|
166
|
Cashflow |
171
|
105
|
6
|
143
|
276
|
113
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.16
|
0.08
|
0.01
|
0.12
|
0.24
|
0.11
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
17.75
|
14.06
|
7.96
|
12.81
|
14.08
|
Eps |
0.42
|
-1.68
|
0.42
|
0.58
|
0.41
|
Price/earnings-ratio |
42.26
|
-8.37
|
18.95
|
22.09
|
20.49
|
Dividend |
0.18
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
1.01 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.43
|
0.0
|
0.0
|
0.0
|
|
Book value |
8.21
|
6.12
|
6.52
|
7.08
|
7.18
|
Market to book |
0.46
|
0.44
|
0.82
|
0.55
|
0.85
|
Cashflow per stock |
0.57
|
0.03
|
0.78
|
1.53
|
0.62
|
Stocks |
185
|
185
|
183
|
181
|
182
|
Market Cap |
3.287.89
|
2.604.38
|
1.454.61
|
2.315.87
|
1.524.73
|
Date
|
Price
|
---|---|
13 Nov 2024
|
8.40
|
08 Nov 2024
|
8.77
|
05 Nov 2024
|
9.00
|
31 Oct 2024
|
9.24
|
29 Oct 2024
|
9.17
|
23 Oct 2024
|
9.26
|
19 Oct 2024
|
9.09
|
16 Oct 2024
|
8.97
|
14 Oct 2024
|
8.96
|
05 Oct 2024
|
9.15
|
02 Oct 2024
|
9.02
|
27 Sep 2024
|
8.82
|
20 Sep 2024
|
8.56
|
17 Sep 2024
|
8.53
|
13 Sep 2024
|
8.56
|
28 Aug 2024
|
8.77
|
26 Aug 2024
|
8.85
|
23 Aug 2024
|
8.90
|
11 Aug 2024
|
8.98
|
07 Aug 2024
|
8.94
|
05 Aug 2024
|
8.78
|
01 Aug 2024
|
9.24
|
30 Jul 2024
|
9.38
|
26 Jul 2024
|
9.57
|
23 Jul 2024
|
9.35
|
16 Jul 2024
|
9.17
|
10 Jul 2024
|
9.50
|
09 Jul 2024
|
9.39
|
04 Jul 2024
|
9.39
|
02 Jul 2024
|
8.66
|